New Dual-Target CAR t therapy aims to outsmart tough blood cancers
Disease control
Recruiting now
This early-phase study tests a new cell therapy called GF-CART01 in 18 adults aged 18-70 with B-cell blood cancers (like lymphoma) that have come back or not responded to standard treatments. The therapy uses a patient's own immune cells, modified to target two markers (CD20 and …
Phase: PHASE1 • Sponsor: GenomeFrontier Therapeutics TW Co., Ltd. • Aim: Disease control
Last updated May 13, 2026 16:00 UTC